Travere Therapeutics (TVTX) Tops Q1 EPS by 3c

Travere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of ($0.82), $0.03 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $48.5 million versus the consensus estimate of $51.92 million.

Cash, cash equivalents and marketable securities, as of March 31, 2022, totaled $603.4 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• BofA lists top 5 themes driving next $1tn in incremental semi sales